Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • Participation
09/23/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
10/01/2021
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.
  • Oncology
  • ACPE Pharmacy
  • Participation
10/14/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • ACPE Pharmacy
  • Participation
10/20/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.